At Rush University Medical Center, we are putting your safety first. For information about COVID-19, see the latest updates. Rush accepts donations to support our response effort, staff, and patients and families.

Excellence is just the beginning.

Translate

French German Italian Portuguese Russian

MYC-Associated B-Cell Lymphomas Treatment Study

Clinical Trial Title: 
Prospective, multi-center phase I/II trial of lenalidomide and dose-adjusted EPOCH-R in MYC-associated B-cell lymphomas.
Clinical Trial Protocol ID: 
15040301
Clinical Trial Investigator Name: 
Parameswaran Venugopal, MD
Clinical Trial Protocol Description: 

Participating in the phase II portion of the trial that will study the side effects and the best dose of lenalidomide when given together with combination chemotherapy to see how well they work together in treating subjects with “double hit” lymphoma.

Clinical Trial Eligibility Criteria: 

In order to participate you must meet the following criteria:

  • Have B-cell lymphoma.
  • Have evidence of c-MYC.
  • Register into the mandatory lenalidomide Risk Evaluation and Mitigation Strategies (REMS) program, and be willing and able to comply with the requirements of the REMS program.
  • Be able to take aspirin (81 or 325 mg) daily as prophylactic anticoagulation.
  • Have an ECOG performance status of 0-2.
  • Have adequate renal and bone marrow function.

You will be excluded from the study if any of the following criteria apply to you:

• Have had prior chemotherapy, radiotherapy, or immunotherapy for lymphoma.
• Have known central nervous system involvement.
• Have known positive HIV status, or positive serology for hepatitis B or C.
• Have prior exposure to pomalidomide or known hypersensitivity to lenalidomide or thalidomide.

This is a partial list of inclusion and exclusion criteria.

Clinical Trial Area: 
Blood Disorders and Hematologic Cancers
Contact Email: 
Contact Phone: 
(312) CANCER-1
Contact Name: 
Rush Cancer Center Clinical Trials Office